GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Hold” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $5.5227.

Several research firms have recently issued reports on GDRX. Mizuho cut their price target on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Wall Street Zen downgraded shares of GoodRx from a “buy” rating to a “hold” rating in a report on Saturday. Raymond James Financial cut shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. UBS Group lowered their price target on shares of GoodRx from $4.25 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. Finally, TD Cowen dropped their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Monday, November 10th.

GoodRx Price Performance

GDRX stock opened at $2.79 on Wednesday. The firm has a 50 day moving average of $3.85 and a 200-day moving average of $4.19. The company has a market cap of $947.02 million, a price-to-earnings ratio of 31.00, a PEG ratio of 1.48 and a beta of 1.20. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. GoodRx has a 12-month low of $2.77 and a 12-month high of $5.81.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The business’s revenue was up .4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.08 EPS. GoodRx has set its FY 2025 guidance at EPS. As a group, equities analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total transaction of $95,084.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.17% of the company’s stock.

Institutional Trading of GoodRx

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in GoodRx by 7.3% during the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock worth $38,947,000 after purchasing an additional 624,182 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of GoodRx by 4.0% during the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock worth $24,001,000 after buying an additional 184,734 shares in the last quarter. Petrus Trust Company LTA grew its holdings in shares of GoodRx by 7.4% during the first quarter. Petrus Trust Company LTA now owns 3,167,015 shares of the company’s stock worth $13,967,000 after buying an additional 216,926 shares in the last quarter. LSV Asset Management raised its position in shares of GoodRx by 517.1% in the third quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock valued at $9,960,000 after buying an additional 1,973,017 shares during the last quarter. Finally, 8 Knots Management LLC purchased a new position in shares of GoodRx during the first quarter valued at approximately $8,106,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.